Enrichment of SMARCA4 mutations in lung carcinomas presenting as cancer of unknown primary [0.03%]
SMARCA4突变在肺癌未知原发灶中的富集现象
Tobias Martinot,Lydia H N Schonewille,Dina Ruano et al.
Tobias Martinot et al.
Objectives: Identifying the primary tumor in cancer of unknown primary (CUP) remains a major clinical challenge. While WGS-based tissue-of-origin (TOO) prediction has improved diagnostic precision, its use is constrained ...
Characterization of the cancer-associated field of injury in the nasal epithelium in never-smokers [0.03%]
非吸烟者鼻黏膜癌症相关损伤域的特征研究
Minyi Lee,Megumi Yokomizo,Ramin Salehi-Rad et al.
Minyi Lee et al.
Lung cancer in never-smokers represents a distinct and growing clinical challenge, yet early detection strategies largely target smokers. Here, we demonstrate that nasal epithelial gene expression alterations previously associated with lung...
Dietary inflammatory index and lung cancer risk: multi-cohort evidence and plasma proteomic profiles [0.03%]
饮食炎性指数与肺癌风险：多队列证据及血浆蛋白质组学特征
Lingli Chen,Yi Feng,Maolin Liu et al.
Lingli Chen et al.
Background: Accumulating evidence links dietary inflammatory potential to cancer, yet its association with lung cancer incidence and mortality remains inconsistent. This study aimed to examine the relationship between the...
Dorine Templement-Grangerat,Chrystèle Locher,Anne Catherine Neidhardt et al.
Dorine Templement-Grangerat et al.
Introduction: The KBP-CPHG observational studies, conducted every 10 years, have shown a significant increase in the proportion of women with lung cancer, rising from 16.0 % in 2000 to 34.6 % in 2020 (P < 0.0001). We repo...
Characterization of a rare EGFR resistance mutation in a lung cancer patient with a long response to osimertinib: case report [0.03%]
奥希替尼长期治疗一例罕见的EGFR耐药突变型肺癌患者的病例报告及特征分析
Beatriz García-Peláez,Núria Jordana-Ariza,Andrés Aguilar-Hernández et al.
Beatriz García-Peláez et al.
Introduction: Osimertinib is the standard of care in first-line therapy for advanced EGFR-mutant NSCLC, but resistance invariably develops through EGFR-dependent or independent mechanisms. ...
Real-world burden of cardiovascular events following immune checkpoint inhibitor therapy: impact on mortality and treatment resumption in 29,503 patients [0.03%]
免疫检查点抑制剂治疗后心血管事件的现实世界负担：对29,503例患者死亡率和恢复治疗的影响
Clemence Rigaux,Dimitri Arangalage,Karissa Adkins et al.
Clemence Rigaux et al.
Background: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but can cause rare, severe cardiotoxicity. The real-world incidence and impact of a broader spectrum of cardiovascular events remains poorly ...
Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study [0.03%]
针对无法手术的III期EGFR突变型NSCLC患者在确定性同期放化疗后使用奥希替尼：LAURA三期临床试验的安全性结果分析
Terufumi Kato,Xiaorong Dong,Toshiaki Takahashi et al.
Terufumi Kato et al.
Background: In the phase III LAURA study, osimertinib demonstrated a statistically significant progression-free survival benefit versus placebo, and a generally tolerable safety profile, after definitive chemoradiotherapy...
Rechallenge with zongertinib after trastuzumab deruxtecan in HER2-mutant lung cancer: A case report [0.03%]
恩美曲妥珠单抗治疗后使用ゾンゲルチニブ治疗HER2突变型肺癌的挽救性治疗：一例报告
Hayato Koba,Yuichi Tambo,Yuya Murase et al.
Hayato Koba et al.
A 65-year-old man with advanced lung adenocarcinoma underwent comprehensive genomic profile testing using a blood sample after completion of standard therapy, which identified a HER2 mutation. The HER2- tyrosine kinase inhibitor (TKI); zong...
Comparative performance of shape-sensing robotic-assisted bronchoscopy and CT-guided transthoracic biopsy in diagnosing peripheral pulmonary lesions [0.03%]
形状感应机器人辅助支气管镜与CT引导下经胸穿刺活检诊断肺外周病变的性能比较
Dakota McNierney,Cody Messick,Morgan Reeve et al.
Dakota McNierney et al.
Background: Lung cancer is the leading cause of cancer mortality. Nonsurgical biopsies are obtained by computed tomography-guided transthoracic biopsy (CTTB) or bronchoscopically. Due to previous limitations in convention...
Refining N1 classification: prognostic validation of N1 subdivision in resected non-small cell lung cancer [0.03%]
NSCLC根治术后N1分期的预后分析及分组优化研究
Shia Kim,In Ha Kim,Ji Yong Kim et al.
Shia Kim et al.
Introduction: Accurate evaluation of nodal metastasis is essential for staging and prognostication of non-small cell lung cancer (NSCLC). The 9th edition of the TNM classification subdivided N2 into single station(N2a) an...